Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 15, 2022 07:00 ET | Source: Imara, Inc.

Imara Reports Full Year 2021 Financial Results and Business Highlights

Completed enrollment in Phase 2b sickle cell disease and beta-thalassemia trials with tovinontrine (IMR-687); expect to report both interim datasets in first week of April 2022 Changed primary...
March 08, 2022 07:00 ET | Source: Imara, Inc.

Imara to Webcast Conference Call of Full Year 2021 Financial Results and Business Highlights

BOSTON, March 08, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
February 10, 2022 07:00 ET | Source: Imara, Inc.

Imara to Present at 11th Annual SVB Leerink Global Healthcare Conference

BOSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
January 25, 2022 07:00 ET | Source: Imara, Inc.

Imara Announces FDA Clearance of Investigational New Drug Application (IND) for Tovinontrine (IMR-687) for Heart Failure with Preserved Ejection Fraction (HFpEF)

Expanding patient base and potential of Imara’s small molecule oral inhibitor of phosphodiesterase-9 (PDE9) alongside hemoglobin disorders Phase 2 trial aims to select HFpEF patients with enriched...
November 08, 2021 07:00 ET | Source: Imara, Inc.

Imara to Report Data Demonstrating the Potential of Tovinontrine (IMR-687) for the Treatment of Heart Failure with Preserved Ejection Fraction (HFpEF)

Preclinical data from three different mouse models of HFpEF to be presented at American Heart Association (AHA) Scientific Sessions HFpEF development to be led by cardiologist Toni Bransford, M.D.,...
October 30, 2019 07:31 ET | Source: Cyclerion Therapeutics, Inc.

Cyclerion Therapeutics Announces Praliciguat Topline Phase 2 Results in Diabetic Nephropathy

– Study did not reach statistical significance on primary endpoint – – Positive trends on primary and secondary endpoints indicate profile that merits further investigation – – Company intends to...
October 30, 2019 07:30 ET | Source: Cyclerion Therapeutics, Inc.

Cyclerion Therapeutics Announces Topline Phase 2 Results for sGC Stimulator Praliciguat in Heart Failure with Preserved Ejection Fraction (HFpEF)

– Study in HFpEF patients did not meet primary endpoint; company discontinuing development of praliciguat in HFpEF – – Conference call to be held at 8:30 a.m. ET today – CAMBRIDGE, Mass., Oct. ...
October 08, 2019 08:00 ET | Source: Cyclerion Therapeutics, Inc.

Cyclerion Therapeutics and Collaborators to Present New Research on the Sickle Cell Disease Patient Journey at Upcoming Medical Meetings

CAMBRIDGE, Mass., Oct. 08, 2019 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company developing soluble guanylate cyclase (sGC) stimulators for...
September 10, 2019 08:00 ET | Source: Cyclerion Therapeutics, Inc.

Cyclerion to Host Webcast Investor Event on Cardiometabolic Programs on September 17

CAMBRIDGE, Mass., Sept. 10, 2019 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company focused on the development of soluble guanylate cyclase...
August 12, 2019 08:00 ET | Source: Cyclerion Therapeutics, Inc.

Cyclerion Therapeutics Reports Second Quarter 2019 Financial Results and Progress on Four Clinical Studies with Data Readouts Anticipated in the Next 12 Months

– Two praliciguat Phase 2 studies for diabetic nephropathy and heart failure with preserved ejection fraction (HFpEF) on track for data readouts in Q4 2019 – – Phase 2 study of olinciguat in sickle...